{"transactions":[{"id":1104581,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-20T07:00:12.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":720,"derivative":{"exercise_price":3.22,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":720},"source":{"system":"sec-edgar","filing":"0000950170-25-088167","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650322/000095017025088167/ownership.xml","form_type":"4"}},{"id":1471673,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T16:00:03.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 20, 2024, the date of the Issuer's 2024 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":0.49,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-24-076182","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650322/000095017024076182/ownership.xml","form_type":"4"}},{"id":1853785,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T16:00:08.000Z","date":"2023-06-17","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2023, the date of the Issuer's 2023 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":2.12,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-23-037284","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650322/000120919123037284/doc4.xml","form_type":"4"}},{"id":2231067,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-15T16:00:10.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":1.98,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-22-036931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650322/000120919122036931/doc4.xml","form_type":"4"}},{"id":2338169,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:04.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":7202,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":65.19,"underlying":"Common Stock","underlying_shares":7202},"source":{"system":"sec-edgar","filing":"0001628280-22-005908","document":"wf-form4_164703370685042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005908/wf-form4_164703370685042.xml","form_type":"4"}},{"id":2338168,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:04.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":61.31,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001628280-22-005908","document":"wf-form4_164703370685042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005908/wf-form4_164703370685042.xml","form_type":"4"}},{"id":2338167,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:04.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":56.5,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001628280-22-005908","document":"wf-form4_164703370685042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005908/wf-form4_164703370685042.xml","form_type":"4"}},{"id":2338166,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:04.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":49.17,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001628280-22-005908","document":"wf-form4_164703370685042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005908/wf-form4_164703370685042.xml","form_type":"4"}},{"id":2338165,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:04.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":13.6,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001628280-22-005908","document":"wf-form4_164703370685042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005908/wf-form4_164703370685042.xml","form_type":"4"}},{"id":2338164,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:04.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":4167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":14.6,"underlying":"Common Stock","underlying_shares":4167},"source":{"system":"sec-edgar","filing":"0001628280-22-005908","document":"wf-form4_164703370685042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005908/wf-form4_164703370685042.xml","form_type":"4"}},{"id":2338163,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:04.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":14.6,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001628280-22-005908","document":"wf-form4_164703370685042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005908/wf-form4_164703370685042.xml","form_type":"4"}},{"id":2338162,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-11T16:22:04.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":3067,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-22-005908","document":"wf-form4_164703370685042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005908/wf-form4_164703370685042.xml","form_type":"4"}},{"id":2338161,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-11T16:22:04.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":4085,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."}],"balance_after":3067,"source":{"system":"sec-edgar","filing":"0001628280-22-005908","document":"wf-form4_164703370685042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005908/wf-form4_164703370685042.xml","form_type":"4"}},{"id":2669047,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T17:27:35.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":7202,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 11, 2021 with the final installment vesting  upon the earlier of the one-year anniversary of the grant date or the date of the next annual stockholders' meeting, and are exercisable once vested."}],"balance_after":7202,"derivative":{"exercise_price":65.19,"expiration_date":"2028-06-11","underlying":"Common Stock","underlying_shares":7202},"source":{"system":"sec-edgar","filing":"0001628280-21-012284","document":"wf-form4_162379243656469.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021012284/wf-form4_162379243656469.xml","form_type":"4"}},{"id":2669046,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T17:27:35.000Z","date":"2021-06-15","kind":"sale","acquired":false,"shares":1223,"price":66.36,"value":81158.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this line item of this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":7152,"source":{"system":"sec-edgar","filing":"0001628280-21-012284","document":"wf-form4_162379243656469.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021012284/wf-form4_162379243656469.xml","form_type":"4"}},{"id":2669045,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T17:27:35.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":3067,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 11, 2022, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":8375,"source":{"system":"sec-edgar","filing":"0001628280-21-012284","document":"wf-form4_162379243656469.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021012284/wf-form4_162379243656469.xml","form_type":"4"}},{"id":2690633,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-28T16:00:27.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on May 26, 2021, the date of the Issuer's 2021 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":4.93,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-036508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650322/000120919121036508/doc4.xml","form_type":"4"}},{"id":2903070,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-20T21:06:58.000Z","date":"2021-01-19","kind":"sale","acquired":false,"shares":1327,"price":80.5,"value":106823.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":5308,"source":{"system":"sec-edgar","filing":"0001209191-21-004585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121004585/doc4.xml","form_type":"4"}},{"id":2945095,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-15T16:07:27.000Z","date":"2020-12-11","kind":"purchase","acquired":true,"shares":5,"price":69.3091,"value":346.5455,"ownership":{"direct":true},"balance_after":6635,"source":{"system":"sec-edgar","filing":"0001209191-20-063452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120063452/doc4.xml","form_type":"4"}},{"id":2952238,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-09T16:03:27.000Z","date":"2020-12-08","kind":"purchase","acquired":true,"shares":5,"price":66.248,"value":331.24,"ownership":{"direct":true},"balance_after":6630,"source":{"system":"sec-edgar","filing":"0001209191-20-062475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120062475/doc4.xml","form_type":"4"}},{"id":2969424,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-11-23T16:47:16.000Z","date":"2020-11-19","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a pro-rated annual option grant to a non-employee director upon appointment to the Board of Directors of the Company. The shares subject to such option vest in twelve equal monthly installments, commencing on November 19, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a pro-rated annual option grant to a non-employee director upon appointment to the Board of Directors of the Company. The shares subject to such option vest in twelve equal monthly installments, commencing on November 19, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":9000,"derivative":{"exercise_price":16.6,"expiration_date":"2030-11-18","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000899243-20-031922","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650322/000089924320031922/doc4.xml","form_type":"4"}},{"id":2969423,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-11-23T16:47:16.000Z","date":"2020-11-19","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest in 36 equal monthly installments over three years from the date of vesting commencement of November 19, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":18000,"derivative":{"exercise_price":16.6,"expiration_date":"2030-11-18","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-20-031922","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650322/000089924320031922/doc4.xml","form_type":"4"}},{"id":3006789,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-14T16:15:31.000Z","date":"2020-10-13","kind":"disposition_to_issuer","acquired":false,"shares":200000,"price":10.69,"value":2138000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."}],"balance_after":0,"derivative":{"exercise_price":23.81,"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-20-028181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320028181/doc4.xml","form_type":"4"}},{"id":3006788,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-14T16:15:31.000Z","date":"2020-10-13","kind":"disposition_to_issuer","acquired":false,"shares":210000,"price":10.78,"value":2263800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."}],"balance_after":0,"derivative":{"exercise_price":23.72,"underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0000899243-20-028181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320028181/doc4.xml","form_type":"4"}},{"id":3006787,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-14T16:15:31.000Z","date":"2020-10-13","kind":"disposition_to_issuer","acquired":false,"shares":350000,"price":3.82,"value":1337000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."}],"balance_after":0,"derivative":{"exercise_price":30.68,"underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000899243-20-028181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320028181/doc4.xml","form_type":"4"}},{"id":3006786,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-10-14T16:15:31.000Z","date":"2020-10-13","kind":"disposition_to_issuer","acquired":false,"shares":89250,"price":34.5,"value":3079125.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of to SPN MergerSub, Inc. (\"Merger Sub\"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., (\"Nestle\"), and Merger Sub (the \"Merger Agreement\"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the \"Offer Price\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement, each Issuer restricted stock unit (\"RSU\") that was outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-028181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320028181/doc4.xml","form_type":"4"}},{"id":3006785,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-10-14T16:15:31.000Z","date":"2020-10-10","kind":"other","acquired":false,"shares":30422,"price":34.5,"value":1049559.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 2,638 shares acquired pursuant to the Issuer's employee stock purchase plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-028181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320028181/doc4.xml","form_type":"4"}},{"id":3029726,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-09-16T17:17:55.000Z","date":"2020-09-15","kind":"tax_withholding","acquired":false,"shares":1642,"price":34.25,"value":56238.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 33,000 restricted stock units (\"RSUs\") which will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes the balance of 35,000 RSUs which will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes the balance of 60,000 RSUs which will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":117034,"source":{"system":"sec-edgar","filing":"0000899243-20-025345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320025345/doc4.xml","form_type":"4"}},{"id":3098248,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-06-26T17:06:01.000Z","date":"2020-06-22","kind":"tax_withholding","acquired":false,"shares":7907,"price":18.02,"value":142484.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,300 restricted stock units (\"RSUs\") which will be settled in common stock upon vesting.  The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the \"Vesting Date\"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 33,000 RSUs which will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes the balance of 35,000 RSUs which will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes the balance of 60,000 RSUs which will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":118676,"source":{"system":"sec-edgar","filing":"0000899243-20-017779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320017779/doc4.xml","form_type":"4"}},{"id":3109521,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-16T19:40:32.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 12, 2020, and are exercisable once vested."}],"balance_after":5000,"derivative":{"exercise_price":61.31,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-20-037102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120037102/doc4.xml","form_type":"4"}},{"id":3109520,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-16T19:40:32.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":2446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 12, 2021, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":6625,"source":{"system":"sec-edgar","filing":"0001209191-20-037102","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120037102/doc4.xml","form_type":"4"}},{"id":3152139,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-05-12T17:25:28.000Z","date":"2020-05-10","kind":"grant","acquired":true,"shares":3300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the \"Vesting Date\"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the \"Vesting Date\"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 33,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 35,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 60,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":126583,"source":{"system":"sec-edgar","filing":"0000899243-20-012860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320012860/doc4.xml","form_type":"4"}},{"id":3217070,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-03-10T20:48:28.000Z","date":"2020-03-10","kind":"purchase","acquired":true,"shares":2665,"price":18.737,"value":49934.105,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 33,000 restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 35,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 60,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":123283,"source":{"system":"sec-edgar","filing":"0000899243-20-007815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320007815/doc4.xml","form_type":"4"}},{"id":3226305,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-03-04T21:42:01.000Z","date":"2020-03-02","kind":"tax_withholding","acquired":false,"shares":3081,"price":23.81,"value":73358.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 33,000 restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 35,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 60,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":120618,"source":{"system":"sec-edgar","filing":"0000899243-20-007103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320007103/doc4.xml","form_type":"4"}},{"id":3230596,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-03T20:37:23.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":23.81,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-20-006853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320006853/doc4.xml","form_type":"4"}},{"id":3230595,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-03-03T20:37:23.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 35,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 60,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":123699,"source":{"system":"sec-edgar","filing":"0000899243-20-006853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320006853/doc4.xml","form_type":"4"}},{"id":3269827,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-02-14T17:23:17.000Z","date":"2019-06-19","kind":"tax_withholding","acquired":false,"shares":7951,"price":20.2,"value":160610.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 52,049 restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 35,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":90699,"source":{"system":"sec-edgar","filing":"0000899243-20-004693","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320004693/doc5.xml","form_type":"5"}},{"id":3488353,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-17T18:38:54.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2019, and are exercisable once vested."}],"balance_after":5000,"derivative":{"exercise_price":56.5,"expiration_date":"2026-06-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-19-037485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037485/doc4.xml","form_type":"4"}},{"id":3488352,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T18:38:54.000Z","date":"2019-06-14","kind":"sale","acquired":false,"shares":170,"price":56.5082,"value":9606.394,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.48 to $56.64, inclusive."}],"balance_after":4179,"source":{"system":"sec-edgar","filing":"0001209191-19-037485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037485/doc4.xml","form_type":"4"}},{"id":3488351,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T18:38:54.000Z","date":"2019-06-14","kind":"sale","acquired":false,"shares":1355,"price":55.8184,"value":75633.932,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.42 to $56.27, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4 to this Form 4."}],"balance_after":4349,"source":{"system":"sec-edgar","filing":"0001209191-19-037485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037485/doc4.xml","form_type":"4"}},{"id":3488350,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T18:38:54.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":2654,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 13, 2020, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units."}],"balance_after":5704,"source":{"system":"sec-edgar","filing":"0001209191-19-037485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037485/doc4.xml","form_type":"4"}},{"id":3630865,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-26T16:05:29.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":210000,"derivative":{"exercise_price":23.72,"expiration_date":"2029-02-22","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0000899243-19-004861","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924319004861/doc4.xml","form_type":"4"}},{"id":3630864,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2019-02-26T16:05:29.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 60,000 restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from June 19, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":98650,"source":{"system":"sec-edgar","filing":"0000899243-19-004861","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924319004861/doc4.xml","form_type":"4"}},{"id":3758405,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2018-11-19T20:12:27.000Z","date":"2018-11-19","kind":"purchase","acquired":true,"shares":50,"price":27.5599,"value":1377.995,"ownership":{"direct":true},"balance_after":63650,"source":{"system":"sec-edgar","filing":"0000899243-18-029386","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924318029386/doc4.xml","form_type":"4"}},{"id":3758404,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2018-11-19T20:12:27.000Z","date":"2018-11-19","kind":"purchase","acquired":true,"shares":3600,"price":27.558,"value":99208.8,"ownership":{"direct":true},"balance_after":63600,"source":{"system":"sec-edgar","filing":"0000899243-18-029386","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924318029386/doc4.xml","form_type":"4"}},{"id":3887859,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-06-19T19:06:14.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 19, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":350000,"derivative":{"exercise_price":30.68,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000899243-18-017243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924318017243/doc4.xml","form_type":"4"}},{"id":3887858,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.0001 par value","published_at":"2018-06-19T19:06:14.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from June 19, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0000899243-18-017243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924318017243/doc4.xml","form_type":"4"}},{"id":3892864,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-15T16:29:03.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2018, and are exercisable once vested."}],"balance_after":5000,"derivative":{"exercise_price":49.17,"expiration_date":"2025-06-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-18-038061","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118038061/doc4.xml","form_type":"4"}},{"id":3892863,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-15T16:29:03.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":3050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 13, 2019, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units."}],"balance_after":3050,"source":{"system":"sec-edgar","filing":"0001209191-18-038061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118038061/doc4.xml","form_type":"4"}},{"id":3907813,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-06-04T20:50:14.000Z","date":"2018-06-01","kind":"tax_withholding","acquired":false,"shares":294,"price":73.73,"value":21676.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 520 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2018."}],"balance_after":23830,"source":{"system":"sec-edgar","filing":"0001209191-18-035180","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919118035180/doc4.xml","form_type":"4"}},{"id":3959919,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-04-19T20:46:55.000Z","date":"2018-04-19","kind":"grant","acquired":true,"shares":1431,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on April 19, 2018 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":23604,"source":{"system":"sec-edgar","filing":"0001209191-18-025593","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919118025593/doc4.xml","form_type":"4"}},{"id":4013877,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-05T21:19:46.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":32000,"derivative":{"exercise_price":48.43,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001209191-18-016427","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919118016427/doc4.xml","form_type":"4"}},{"id":4013876,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-05T21:19:46.000Z","date":"2018-03-01","kind":"tax_withholding","acquired":false,"shares":441,"price":48.43,"value":21357.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."}],"balance_after":22173,"source":{"system":"sec-edgar","filing":"0001209191-18-016427","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919118016427/doc4.xml","form_type":"4"}},{"id":4013875,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-05T21:19:46.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 7 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2017."}],"balance_after":22614,"source":{"system":"sec-edgar","filing":"0001209191-18-016427","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919118016427/doc4.xml","form_type":"4"}},{"id":4241125,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-08-07T20:54:08.000Z","date":"2017-08-03","kind":"tax_withholding","acquired":false,"shares":940,"price":62.59,"value":58834.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units."}],"balance_after":16107,"source":{"system":"sec-edgar","filing":"0001209191-17-047910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919117047910/doc4.xml","form_type":"4"}},{"id":4282564,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-06-14T19:43:35.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over one year with one twelfth vesting on July 13, 2017, and the remainder of the shares vesting monthly over the following eleven months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":150000,"derivative":{"exercise_price":1.36,"expiration_date":"2024-06-13","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-17-039977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919117039977/doc4.xml","form_type":"4"}},{"id":4297758,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-06-02T01:18:20.000Z","date":"2017-06-01","kind":"tax_withholding","acquired":false,"shares":320,"price":56.61,"value":18115.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 407 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 28, 2017."}],"balance_after":17047,"source":{"system":"sec-edgar","filing":"0001209191-17-036979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919117036979/doc4.xml","form_type":"4"}},{"id":4413268,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-03-01T22:36:07.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":30000,"derivative":{"exercise_price":88.8,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-17-016051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919117016051/doc4.xml","form_type":"4"}},{"id":4413267,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-03-01T22:36:07.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":16960,"source":{"system":"sec-edgar","filing":"0001209191-17-016051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919117016051/doc4.xml","form_type":"4"}},{"id":4450341,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-02-14T20:16:17.000Z","date":"2017-02-13","kind":"grant","acquired":true,"shares":41666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest over four months with 25% vesting on March 13, 2017, and the remainder of the shares vesting monthly over the following three months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":41666,"derivative":{"exercise_price":1.46,"expiration_date":"2024-02-13","underlying":"Common Stock","underlying_shares":41666},"source":{"system":"sec-edgar","filing":"0001209191-17-010890","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919117010890/doc4.xml","form_type":"4"}},{"id":4450340,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":78261,"kind":"person","name":"Dallas Jayson Donald Alexander","position":1,"cik":"0001650322","reported_name":"Dallas Jayson Donald Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-02-14T20:16:17.000Z","date":"2017-02-13","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over one year with one twelfth vesting on March 13, 2017, and the remainder of the shares vesting monthly over the following eleven months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":75000,"derivative":{"exercise_price":1.46,"expiration_date":"2024-02-13","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-17-010890","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919117010890/doc4.xml","form_type":"4"}}]}